厄贝沙坦对高血压并发心力衰竭患者心功能的影响

The effect of irbesartan on ventricular function in hypertensive patients with heart failure

目的 :观察血管紧张素Ⅱ受体阻滞剂厄贝沙坦的降压疗效和对心功能的影响。方法 :试验组 (n =4 0 )口服厄贝沙坦 15 0mg ,qd ,连用 4周 ;对照组 (n =36 )口服卡托普利 12 .5mg ,bid或tid ,连用 4周 ,用药期间仔细检查体格及心电图 ,给药前后行超声心动图计算射血分数 (EF)和E/A比值 ,评定心功能变化。结果 :试验组SBP和DBP都有明显降低 ,而对照组改变不明显 ,2组间比较差异非常显著 ;2组治疗后心功能都有明显改善 ,试验组总有效率为 80 % ,对照组为 6 1% ,2组比较差异有显著性 ;2组治疗后LVEF均升高 :试验组 0 .4 6± 0 .0 7vs 0 .4 1±0 .0 6 (P <0 .0 5 ) ,对照组 0 .4 2± 0 .0 6vs 0 .4 0± 0 .0 5 (P >0 .0 5 ) ;E/A比值升高 :试验组为 1.0 6± 0 .13vs 0 .5 8±0 .15 (P <0 .0 1) ,对照组 0 .76± 0 .12vs 0 .5 7± 0 .14 (P <0 .0 5 )。试验组好转更明显。结论 :厄贝沙坦有利于缓解心衰症状 ,改善其收缩功能和舒张功能 ;其疗效优于卡托普利。

Objective:To observe the efficacy and effect on heart failure of irbesartan.Method:76 hypertensive patients with CHF(congestive heart failure) were divided to receive oral irbesartan 72～ 100mg·d -1 ( n= 40) for 4 weeks or oral captopril 12.5mg 2～3 times daily ( n= 36) for 4 weeks.Pre and post treatment physical examination,ECG(electrocardiogram),EF(ejection fraction) and E/A ratio were performed during treatment.Result:The SBP and DBP were significantly decreased in the active group but not in the control group.The geart function were significantly improved in both groups,with a total effective rate of 80% in the active group and of 61% in the control group.The LVEF and E/A ratio were increased in both groups.Conclusion:Irbesartan is suitable to relieve CHF and its effect in improvement of SBP and DBP is better than those of captopril.